How Executives Should Select Life Science Finance Consulting Support

Finance and accounting look very different for life science companies than they do in more traditional businesses. Many biotech and medtech companies spend years navigating research, clinical development and regulatory milestones before revenue becomes predictable. During that time, leadership teams still have to manage investor expectations, funding timelines, hiring decisions and operational growth, often with relatively lean internal infrastructure. As a result, executives evaluating outside finance support are usually looking for more than bookkeeping or transactional accounting help. They need partners that can turn complex development activity into clear financial visibility for management teams, boards and investors.

In early-stage life sciences companies, cash management tends to shape nearly every strategic decision. Burn rate, runway, hiring plans and milestone spending are not just finance metrics; they directly influence how long a program can continue advancing. The strongest finance partners understand that reality and help companies build reporting structures that support fast decision-making without creating unnecessary overhead too early. For some businesses, that may mean disciplined monthly closes, board reporting and financial modeling during the venture-backed growth stage. Later, the focus often shifts toward commercialization readiness, inventory planning, revenue recognition and more sophisticated operational controls as products move closer to market.

At the same time, life science companies face increasing pressure to maintain financial credibility as they grow. Investors expect clear reporting around capital use, auditors require defensible records and potential acquirers or public-market advisors often begin reviewing diligence materials long before a transaction is finalized. That creates a need for finance teams that can handle both day-to-day accounting work and more technical issues such as equity accounting, audit preparation, SEC readiness, stock-based compensation and transaction support. The challenge for many companies is finding the right level of expertise without building an oversized finance organization too early in the company’s lifecycle.

Flexibility becomes especially important because biotech growth rarely follows a smooth or predictable path. Funding cycles, clinical trial progress, regulatory reviews and commercialization timelines often shift unexpectedly. Some companies may need heavier financial support during fundraising or diligence periods, then return to a leaner operating model while waiting for the next development milestone. The most effective finance partners are usually the ones that can scale support up or down as those needs change while still maintaining continuity and institutional knowledge over time.

Another factor executives often underestimate is the connection between finance support and broader organizational growth. As companies mature, outside advisors frequently become involved not only in accounting and reporting, but also in recruiting finance talent, strengthening internal processes and helping leadership determine when it makes sense to transition responsibilities in-house. In life sciences, where growth can accelerate quickly after a financing event, regulatory milestone or acquisition discussion, that adaptability can become extremely valuable.

Murdock Martell focuses specifically on finance, accounting and related HR support for life science, medtech, diagnostics and medical device companies. Its services include board reporting, CFO advisory, financial modeling, budgeting, cash management, technical accounting, HR compliance and finance-focused recruiting. The firm’s structure, which pairs senior oversight with scalable day-to-day support, is particularly relevant for early-stage and growth-stage companies trying to balance cost discipline with increasing financial complexity. For executives looking for finance support that can evolve alongside the business rather than forcing a fixed operating model too early, Murdock Martell offers a practical and industry-aligned approach.